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Fig. 2. Donor age and CD8 cell dose.
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ported that a high CD8 T-cell content of peripheral blood (PB)
stem-cell grafts was associated with improved OS in reduced
intensity alloSCT (Reshef et al, Tandem, 2014). In this study
we examined whether donor age correlated with graft T-cell
content, and whether CD8 T-cell content may inform the
selection of an optimal donor.
Methods: We studied 200 patients (pts) who underwent PB
alloSCT after Flu/Bu2 conditioning (2007 to 2014). Cumula-
tive incidence and Cox regression analyses were used to
evaluate associations between cell doses and outcomes, with
adjustment for signiﬁcant covariates.
Results
Patients
The median age was 62 (range 21-76) and diseases
included AML (86), MDS (44), NHL (30), ALL (11), CLL (8) and
others (21). Pts were allografted from HLA-matched (86%) or
mismatched (14%); sibling (42.5%) or unrelated (57.5%)
donors.Outcomes
A higher CD8 cell dose was associated with a decreased
risk of relapse and improved OS. The adjusted hazard ratios
(aHR) per 1 x 108/kg CD8 cells were: relapse 0.43 (95% CI
[0.23 e 0.81]), p ¼ 0.009; OS 0.57 (95% CI [0.33 e 0.97]), p ¼
0.04. A cutoff of 0.72 x 108/kg CD8 cells optimally dichoto-
mized pts with differing OS. Pts who received a CD8hi
(>¼0.72) graft had signiﬁcantly improved OS (aHR ¼ 0.53, p
¼ 0.007; Fig 1). The 1-year survival rates were 77.1% forFig. 3. Survival of recipients (age>60) is better with young unrelated donors
and a CD8hi graft.CD8hi grafts and 50.2% for CD8lo grafts (p ¼ 0.0002). CD3,
CD4 and CD8 doses were not associated with GvHD or NRM.
Donors
Donor age inversely correlated with CD8 cell doses (r ¼
-0.44, p < 0.0001; Fig 2). All donors over age 60 provided a
CD8lo graft while 45% of donors under age 40 provided a
CD8hi graft. In recipients over age 60 (n¼118; Fig 3), OS was
better for patients allografted from young unrelated donors
with a CD8hi graft compared to older sibling donors (p ¼
0.002) or young unrelated donors with a CD8lo graft (p ¼
0.002). The OS beneﬁt was driven by a reduction in relapse
risk without signiﬁcant differences in GVHD or NRM. We
then investigated whether a high CD8 cell dose could be
predicted during donor screening. We found that donors
(n¼23) whose grafts contained a higher CD8 cell dose had
higher %CD8 cells (r ¼ 0.69, p ¼ 0.0004) and lower CD4/8
ratio (r ¼ -0.55, p ¼ 0.007) in a screening blood sample.
Conclusion: A higher CD8 cell dose is associated with
improved survival after reduced intensity alloSCT. Young
unrelated donors with CD8hi grafts lead to better survival
compared to older sibling donors. Donor selection based on
predicted CD8 cell dose should be considered in prospective
trials of reduced intensity alloSCT.
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Introduction: Delayed neutrophil recovery after myelo-
ablative DCBT (median 25 days in adults) is frequent &
associated with prolonged hospitalization & increased
transplant-related mortality.
Methods:We investigated DCBTcombined with haploCD34+
cells to speed myeloid recovery.
Results: Between 9/2012-8/201416/55 (29%) eligible patients
(pts) could not receive DCBT-haplo as they had no haplo (n ¼
10) or had no CB  no haplo graft (n ¼ 6). 39 pts (median 48
years, range 15-68) with high-risk hematologic malignancies
[30 acute leukemias (25 morphologic CR or aplasia, 5 not in
CR) & 9 advanced lymphomas] underwent DCBT-haploCD34+
after myeloablation (2 high-dose Cy/Flu/TBI-1375, 37 reduced
intensity Cy/Flu/Thio/TBI-400) with CSA/MMF & no ATG. CB
units had a median infused TNC x 107/kg of 2.30 (larger unit)
& 1.86 (smaller unit), & a median donor-recipient HLA-allele
match of 5/8 (range 2-7/8). Haplo-donors (median 37 years,
range 15-71) had a median 4/8 (range 4-6/8) donor-recipient
HLA-match. The median infused haploCD34+ cell dose was
Figure.
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(range 0.3-13.7). One pt died early post-transplant. In 38
evaluable pts, 37/38 (97%) recovered neutrophils (median day
13, range 11-38) whereas 1/38 with donor-speciﬁc HLA-Abs
(DSA) to the haplo & both CB units had haplo/CB rejection.
Additionally, one of the 37 pts with early neutrophil recovery
had haplo rejection & CB graft failure in the setting of very
low dominant CB unit CD34+ cell dose. The remaining 36 pts
had both sustained CB engraftment & universal haplo-rejec-
tion as follows (examples in Figure): 20/36 (56%) pts had a
haplo-bridge without recurrent neutropenia (Fig. A), 5/36
(14%) had transient haplo-engraftment with second nadir
(Fig. B), & 11/36 (30%) had no haplo-engraftment & delayed
CB-mediated neutrophil recovery (median 26 days, range
15-33, Fig. C). Haplo rejection & sustained CB engraftment
was associated with dominant unit-derived peripheral
blood T-cells (detected day +28). There was no association
between the haplo-bridge duration & the haploCD34+ cell
dose (above a dose of 2.0 x 106/kg) or the haplo-dominant
CB unit HLA-match (median 3/8). 29/38 (76%) pts
developed pre-engraftment syndrome (PES, median onsetday 10, range 7-15). PES was severe in 3/38 (8%) pts but all
resolved with corticosteroids.
Conclusions: DCBT-haploCD34+ is feasible in most pts &
neutrophil engraftment is enhanced. However, the haplo-
bridge is not guaranteed & given the haplo-graft can be
rapidly rejected the quality & dose of the CB unit(s) is critical.
Low haplo-graft dose & haplo-DSA are likely relevant in
haplo engraftment whereas the dominant CB unit-haplo
HLA-mismatch is not (possibly due to the high degree of
mismatch observed between all haplo & CB grafts). Finally,
PES is common after DCBT-haplo, may be severe, & requires
early corticosteroid therapy.
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